key: cord-1014987-z49gl5i1 authors: Cohen, A. J.; Glick, L. R.; Lee, S.; Kunitomo, Y.; Tsang, D. A.; Pitafi, S.; Valda Toro, P.; Zhang, E.; Datta, R.; Dela Cruz, C. S.; Gautam, S. title: Nonutility of procalcitonin for diagnosing bacterial pneumonia in COVID-19 date: 2022-04-05 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2022.03.29.22272960 sha: a340571ac58bb4928190c119dd3136a89917ef26 doc_id: 1014987 cord_uid: z49gl5i1 Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection. To do so, we identified 185 patients with severe COVID-19 who underwent lower respiratory culture; 85 had superinfection. Receiver operating characteristic curve analysis showed that procalcitonin at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). We conclude that static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19. 1 Text: Bacterial pneumonia is an important complication in patients hospitalized with COVID-19. Its incidence approaches 45% in those receiving mechanical ventilation,(1) and it is associated with increased 28-day mortality. (2) However, establishing the diagnosis of bacterial superinfection is challenging due to its shared clinical features with severe COVID-19, including fever, hypoxemia, and radiographic infiltrates. A further obstacle to diagnosing bacterial infection is the hesitance to obtain lower respiratory cultures (LRCx) due to the potential risk of SARS-CoV-2 aerosolization. Hence, there is considerable interest in identifying effective noninvasive diagnostics for superinfection in COVID-19. Procalcitonin (PCT) is an inflammatory biomarker that has been used as an adjunctive serum test for bacterial pneumonia for over 20 years. investigators have argued for its efficacy. (5) (6) (7) Notably, these studies were limited to patients with co-infection upon presentation to the hospital, which is rare compared to secondary bacterial pneumonia, defined as occurring > 48 hours after admission. (9) In addition, the reported cohorts included patients with varying disease severity, which may confound the interpretation of PCT in COVID-19. (10) In line with this hypothesis, we have demonstrated that PCT levels are associated with clinical severity in non-COVID respiratory viral infection. (11) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.03.29.22272960 doi: medRxiv preprint Therefore, we sought to evaluate the diagnostic utility of PCT for bacterial superinfection in COVID-19specifically in hospitalized patients with severe disease. To do so, we performed a retrospective cohort study of adult patients admitted to Yale New Haven Hospital between January 3, 2020 and July 1, 2020 with severe COVID-19, as defined Data were missing at a rate of less than 15% for all variables. Statistical analysis was conducted using the R software environment (V.3.6.0, Vienna, Austria). To determine significance (defined as p < 0.05), the Chi-squared test or Kruskal-Wallis test was performed due to non-normal data distributions. Spearman's rank correlation coefficient was utilized for regression analysis due to the likelihood of non-linear relationships between biomarkers. The study was approved by Yale's institutional review board All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.03.29.22272960 doi: medRxiv preprint (approval #2000023067). Informed consent was not required due to the noninterventional study design. This approach identified 1308 patients hospitalized with COVID-19 during the study period. Of these, 185 had both severe COVID-19 and a LRCx; 100 had no bacterial growth and 85 had culture-proven superinfection. As shown in Table 1 , these groups were well-matched in terms of demographic and clinical variables. Importantly, the groups demonstrated similar disease severity as indicated by organ failure, intensive care unit (ICU) admission, and mortality. In addition, >70% of LRCx were obtained after 48 hours of admission, thus focusing the analysis on secondary bacterial pneumonia. The distribution of bacterial etiologies showed a predominance of Staphylococcus aureus (34.7%) and Pseudomonas aeruginosa (12.2%), consistent with prior reports. (4, 9) PCT was similar in patients with pure viral infection compared to those with bacterial superinfection (Fig. 1A) . The area under the receiver operating characteristic curve (AUROC) for identifying bacterial pneumonia was 0.52 (95% CI: 0.43-0.60), indicating that PCT is an ineffective test for superinfection in severe COVID-19 (Fig. 1B) . Importantly, we noted that 63.2% of patients had received antibiotics within 24 hours of LRCx. To determine whether antibiotic exposure influenced the diagnostic utility of PCT, we evaluated the AUROC in exposed vs unexposed patients. This analysis revealed similarly poor performance in both subgroups: AUCexposed = 0.49; AUCunexposed = 0.50. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.03.29.22272960 doi: medRxiv preprint Using a cutoff of 0.5 ng/mL, the sensitivity and specificity of PCT were unacceptably low at 33% and 60%, respectively, and the negative predictive value was 51%. PCT, in fact, represented an inferior test for superinfection compared to several non-specific inflammatory biomarkers, including ferritin ( Table 2 ). In contrast, we found that PCT was more effective at predicting severe disease within the study population, as indicated by the AUROC for organ failure, ICU admission, and death. It is important to note that patients were identified retrospectively in this study according to receipt of LRCx; respiratory cultures were not obtained in all patients. Consequently, these data should not be used to estimate the incidence of bacterial superinfection in our cohort. Additionally, the study was restricted to patients with severe disease, in whom baseline PCT is often elevated.(10) As such, it was not designed to assess the utility of low PCT in ruling out bacterial pneumonia during mild COVID-19. Taken together, our findings suggest that PCT represents a marker of disease severity rather than bacterial superinfection in COVID-19, as recently shown in influenza and other viral respiratory infections.(11) Accordingly, we propose that PCT be interpreted as a general indicator of the inflammatory host response, which may derive from superinfection or severe COVID-19 itself. Indeed, PCT correlated closely with several other non-specific immune biomarkers in our study including ferritin (Spearman's ρ = 0.45, p < 0.001) and CRP (Spearman's ρ = 0.51, p < 0.001) (Fig. 1C) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.03.29.22272960 doi: medRxiv preprint In the absence of specific clinical, radiographic, and biochemical tests for bacterial pneumonia in COVID-19, direct microbiologic sampling may represent the optimal means of identifying this important complication.(1) Ongoing evaluation of the safety and efficacy of routine LRCx for the diagnosis of superinfection will be needed. (13) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Definitions: Shock (Systolic blood pressure < 90); renal insufficiency (creatinine > 1.5) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 5, 2022. ; https://doi.org/10.1101/2022.03.29.22272960 doi: medRxiv preprint Bacterial superinfection pneumonia in patients mechanically ventilated for COVID-19 pneumonia Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: A european multicenter comparative clinical trial Personalizing the Management of Pneumonia Limited utility of procalcitonin in identifying communityassociated bacterial infections in patients presenting with coronavirus disease 2019 Creactive protein and procalcitonin for antimicrobial stewardship in COVID-19 Procalcitonin to guide antibacterial prescribing All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Biomarkers for antimicrobial stewardship: A reappraisal in COVID-19 times? Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Bronchoscopy on intubated patients with COVID-19 is associated with low infectious risk to operators No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted